| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Mainstream news |
| Population | Women |
| Source | The Daily Perspective |
| URL | tdp-frontend.pages.dev/article/2026-02-27-women-pay-more-for-testosterone-than-men-and-experts-want-answers-019516e5 (opens in a new tab) |
Specific Claim Evaluated
Testosterone is recognized as beneficial for women with low sexual desire after menopause and appears generally safe when used appropriately, but long-term clinical trial data in women are limited.
Primary Research Supporting or Contradicting the Claim
The global consensus statement identifies hypoactive sexual desire disorder in postmenopausal women as the only evidence-based indication (Davis et al., 2019). A meta-analysis of randomized trials found testosterone effective for postmenopausal women with distressing low sexual desire, with no serious adverse events over short-term follow-up and more acne and hair growth than placebo (Islam et al., 2019).
Corrected Evidence-Based Interpretation
The article is correct. Safety data are limited to about 24 months of physiologic dosing, and long-term breast and cardiovascular safety remain unestablished.
Rationale for Grade
The site describes its byline as an artificial editorial persona, which is a disclosure issue rather than an accuracy issue. The evaluated claims match the consensus position and the randomized evidence, including the limitation on long-term data.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD." - Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. PMID
Supporting excerpt: "Testosterone is effective for postmenopausal women with low sexual desire causing distress"